Novo Nordisk Buys Corvidia Therapeutics to Expand Cardio-Renal Disease Presence

Novo Nordisk is acquiring Massachusetts-based Corvidia Therapeutics with a goal of expanding its presence in cardio-renal disease therapies.

The Danish drugmaker will acquire Corvidia’s ziltivekimab, an anti-inflammatory monoclonal antibody currently being studied for reducing cardiovascular events in chronic kidney disease patients. 

Corvidia’s shareholders will receive an upfront payment of $725 million and will be eligible for future payments that could total $2.1 billion.